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Four tetrandrine (TET) derivatives (IVa-IVd) have been synthesized by Suzuki reaction of boronic acid derivatives and 
5-bromo-tetrandrine obtained by bromination using tetrandrine as the starting material. The structures are analyzed by 1H
NMR, 13C NMR and ESI-MS. The inhibition activities of IVa-IVd against HL60 and A549 cancer cell lines have been
investigated by CCK-8 assay. The compounds having significant (P <0.040) inhibition activities are secondarily screened by
MTT assay. The inhibitory activities of IVa-IVd against protein tyrosine kinases (PTKs) are tested by ELISA. The results
show that IVa, IVb and IVc exhibit significant inhibition activities against the two cancer cell lines. The IVb and IVc show
highly significant (P <0.001) inhibition activities against fibroblast growth factor receptor 1 (FGFR1).
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Tetrandrine (TET) is isolated from the roots of 
Stephania tetrandra (S. Moore) (Menispermaceae) 
which is commonly used in traditional Chinese 
medicine as an antirheumatic, anti-inflammatory and 
antihypertensive agent. As the main component of the 
alkaloid extracted from the root tuber of S. tetrandra 
and S. japonica (Japanese stephania), TET has a wide 
range of pharmacological effects viz. antiplatelet 
aggregation, Ca
2+
 channel block, immunosuppressive 
and free radical scavenging effects
1
. In recent years, 
its antitumor effect has attracted much attention
2
. 
Tetrandrine has diverse anti-inflammatory, immuno-
suppressive and cytoprotective effects
3
. It is the lead 
compound and its structure is modified by protein 
tyrosine kinase (PTKs) family plays an important role 
in cell growth, proliferation and differentiation. 
However, gene mutation, gene fusion and other 
pathological mechanisms can lead to the continuous 




TET has been used as an antifibrotic drug to treat 
the lesions of silicosis in China since the 1960s. It is 
relatively non-toxic to humans, even at the 
administration of 240 mg, intramuscularly (i.m.) 
thrice daily. TET exhibited stronger activity to reverse 
drug resistance to daunorubicin, vinblastine and 
doxorubicin (DOX) in leukemia cells
5
. The c-Met is 
the prototype member of a subfamily of RTKs, which 
includes Ron, which is structurally distinct from other 
RTK families, c-Met signaling is implicated in a wide 
variety of human malignancies in various cancers
6
. 
Under normal conditions, the balance is maintained by 
the antagonistic regulation of tyrosine kinase and 
tyrosine phosphatase
7
. It is a research hotspot of 
antitumor drugs to block the signal transmission of 
tumor cells by tyrosine kinase to achieve the purpose 
of tumor treatment. 
Materials and Methods 
Instruments and reagents 
ZF type three purpose ultraviolet analyzer; 
Advance-500MHz superconducting NMR (CDCl3 as 
a solvent, TMS as internal standard); Agilent 1100sl 
type ion trap mass spectrometer; molecular device 
SPECTROMAX 190 type enzyme labelling 
instrument; smart cell-CO2 type incubator and SW-2f 
type ultra-clean workbench were used in this study. 
Human lung cancer cell line (A549), and human 
promyelocytic leukemia cell line (HL60) were 
purchased from Sigma-Aldrich Co.; while as DMEM/ 
high glucose medium, 0.25% trypsin solution and 
protein tyrosine kinase (PTKs) were procured from 
Shanghai Institute of Medicine. All reagents used 
were of analytical grade. 
Synthesis 
The bromination of tetrandrine was carried out in 
the presence of trifluoroacetic acid and stereospecific 
cross-coupling on brominated alkene with palladium-




catalyst as shown in Scheme 1
8
. Four new phenyl 
substituted tetrandrine were synthesized.  
 
Synthesis of compound II 
A volume of 0.5 mL of I, 10 mL of trifluoroacetic 
acid, and 5 mL of water were added in a single neck 
bottle, stirred to dissolve them; slowly injected with 
0.6 mL bromine, acetic acid (2.5 mL) solution, and 
made them to react in an ice salt bath for 2.5 h. For 
quenching, 25 mL of ice water was added. Ammonia 
water was added for maintaining acidic nature of 
product. Product was extracted using dichloromethane 
(2×100 mL), and combined with the organic phase, 
washed with saturated salt water (3×25 mL), dried 
with anhydrous sodium sulfate, and the solvent was 
evaporate under reduced pressure. The residue was re-
crystallized with ether and purified by silica gel 
column chromatography (eluent: V (methanol): V 
(ethyl acetate): 7:3). The yield of white amorphous 
powder was 88%. 
 
Synthesis of IVa-IVd 
About 135 mg (0.1 mmol), 10 mL toluene and  
2.5 mL of water were added to the three-necked flask, 
and then stirred to dissolve the contents. About  
1.0 mol of potassium acetate (AcOK) was added, and 
then vacuumed and charged with nitrogen for many 
times in 20℃ ultrasonic degassing for 20 min. Pd 
(CH3COO)2 110 mg and 4-biphenyl-phenyl boric acid 
(IIIa) 30.1 mg (0.2 mmol) were added, and the 
reaction was carried out under the condition of reflux 
(90℃) protected by nitrogen for 8 h. Contents were 
cooled to room temperature (37℃), added with 3 mL 
distilled water for quenching reaction. After filtration, 
15 mL ethyl acetate were added to the filtrate, washed 
with saturated salt water (3×50 mL), dry it with 
anhydrous sodium sulfate, evaporate and remove the 
solvent under reduced pressure, and purify 5-(4-bi-
phenyl) tetrandrine (IVa) by TLC [developer: V 
(dichloromethane): V (methanol): V (ethyl acetate): V 
(petroleum ether) = 15:1:1:1] 
 
Determination of biological activity 
Cell Counting Kit-8 (CCK-8), sensitive colorimetric 
assay was used to determination of cell viability in 
cell proliferation and cytotoxicity assays. The cell 
density was adjusted to 5.0 × 10
4
 cells/mL after the 
cells were digested with 0.25% trypsin. Each cell 
suspension was inoculated with 100 μL of cell culture 
into 96-well plate. The cells were cultured in an 
incubator with 5% CO2 at 36℃ for 12 h. Each well 
was added with different concentrations of drugs, 
each group had three wells. The control group was 
added with the same volume of medium as the 
volume of drug added to other wells. All groups were 
cultured in an incubator containing 5% CO2 at 36℃ 
for 72 h before the termination of culture growth. 
Each well was added with 10 μL LCC-8 solution, 
mixed well, and incubated in the cell incubator for 1 h 
to detect the OD value of each well at the wavelength 










Scheme 1 — Schematic for the bromination of tetrandrine for synthesis of the desired compounds (Iva-IVd)   





HL60 and A549 cells were inoculated in 1640 
medium containing 10% fetal bovine serum, 100 
µg/mL penicillin, and 100 μg/mL streptomycin and 
cultured in 5% CO2 incubator at 36℃. Logarithmic 
growth phase cells were used. 
MTT active re-screening was done when the 
concentration was 10 μmoL/mL, i.e., the compounds 
with inhibition rates above 50% were screened by the 
MTT method. About 5 mg/mL MTT 20L was added 
into each well and kept in the incubator for 3-4 h. 
Added 100 μL solution into each hole, kept the 
solution in the incubator overnight, and made the 
crystal fully dissolved, and measured the absorption at 
570 nm. The IC50 of each tumor cell was calculated 
by the software. 
 
Determination of PTK inhibitory activity 
The reaction substrate poly (Glu, Tyr) 4:1 was 
added to 2.0 µg/mL-1125 µL well-coated enzyme 
plate was diluted by PBS enzyme without K, and the 
reaction was carried out at 36℃ for 12 h. Discarded 
the liquid from the wells and washed the plate with t-
PBS [including 0.1% Tween-20 PBS without K+, 200 
µL/well] thrice, each time for 5 min. Dried the 
enzyme plate at 36℃ for 90 min and added 49 μL 
ATP solution diluted by reaction buffer [50 
mmol/mL-HEPES pH 7.4, 50 mmol/mL-MgCl, 0.5 
mmol/mL-MnCl, 0.2 mmol mL Na3VO4, 1 mmol/mL-
DTT], added 1.0 μL diluted solution of each 
compound to be tested in each well, and then add 50 
μL CMET, ALK, FGFR1, RET, EGFR, ErbB2 kinase 
domain recombinant protein diluted by reaction buffer 
to start the reaction. Each experiment was to set with 
two wells without the ATP control well. The reaction 
was carried out in a shaker (100rpm) at 36℃ for 1 h. 
The liquid was discarded from the well and the plate 
was washed with t-PBS thrice and added with 100 µL 
of py99 diluent (the antibody was diluted with 5 
mg/mL t-PBS 1:500) in each well, and left to react for 
0.5 h at 36℃. Later discarded the liquid from the 
wells and washed the plate with t-PBS for thrice and 
added horseradish peroxidase-labeled sheep anti-
mouse second antibody diluent (the antibody was 
diluted with t-pbs1: 2000 containing 5 mg/ mL), 100 
μL /well, and left to react in a shaker at 36℃ for 0.5 
h. Discarded the liquid and washed the plate with t-
PBS thrice. Added 100 µL /well of OPD colour 
developing solution of 2 mg/mL [dilute with 0.1 
mmol/mL-citric acid/sodium citrate buffer (pH 5.4) 
containing 0.03% H2O2, and stopped the reaction at 
25℃ for 1-10 min in dark/light, added 2 mol/mL 
H2SO4 well to stop the reaction, read with the enzyme 
scale. The OD value of each sample was determined 
at 490 nm. The IC50 was obtained by a four-parameter 
regression method with software attached to the 




Results and Discussion 
Palladium-catalyzed Suzuki reaction is an 
important reaction for the construction of C-C bond 
compounds. It has the advantages for wide range of 
substrates, offers mild reaction conditions, and good 
regioselectivity. With the help of the Suzuki reaction, 
scientists have analysed hydratoxin and natural 
products of polyketones, diopside. In this paper, four 
new tetrandrine derivatives (IVa-IVd) were 
synthesized by Suzuki reaction after the 5-selective 
bromination of I and the structures were analysed by 
various analytical methods including 1H NMR, 13C 
NMR and ESI-MS. Among them, the synthesis of II is 
the key step of this experiment. When the drop 
acceleration of bromine is too fast, the temperature of 
the system exceeds 15℃ due to the exothermic 
reaction process, and more impurities are produced. 
By adjusting the drop acceleration of bromine, 
keeping the reaction temperature below 15℃, the 
impurities are reduced, and the yield is 94%, which is 
suitable for large-scale preparation. Suzuki reaction 
requires strict deaeration, and the presence of oxygen 
will reduce the yield. The whole process is carried out 
in a nitrogen atmosphere. After treatment, thin layer 
chromatography was used. Due to the similar polarity 
of IV and II, the second expansion was carried out 
during the experiment, which made the RF value of 
IV and II different greatly and separated. 
 
Analysis of structural data 
5-(4-methoxyphenyl) tetrandrine (IVa) 
Light yellow solid; yield 56%; 1H NMR (500 MHz, 
CDCl3) δ (ppm): 7.37 (dd, J = 8.1 Hz, 1H), 7.17 (dd, J 
= 8.3 Hz, 1H), 6.93 (s, 1H), 6.89 (d, J = 3.5 Hz, 1H), 
6.83 (dd, J = 7.9 Hz, 1H), 6.61 (d, J = 1.4 Hz, 1H), 
6.58 (d, J = 2.3 Hz, 1H), 6.56–6.52 (m, 3H), 6.33 (dd, 
J = 8.2, 2.1 Hz, 1H), 6.04 (s, 1H), 3.87(s, 3H), 3.73 (s, 
3H), 3.67 (s, 1H), 3.49 (s, 1H), 3.47 (s, 3H), 3.45 (s, 
1H), 3.41 (s, 3H), 3.37 (s, 1H), 3.31 (s, 1H), 3.24 (s, 
3H), 3.07–2.91 (m, 3H), 2.88–2.73 (m, 5H), 2.68 (s, 
1H), 2.67 (s, 3H), 2.32 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ = 161.22, 159.03, 154.75, 150.36, 149.40, 




148.64, 148.10, 145.06, 142.65, 136.07, 133.61, 
132.81, 132.42, 131.47, 129.22, 128.93, 128.80, 
126.87, 123.88, 122.90, 121.52, 121.07, 119.23, 
117.13, 112.34, 113.93, 112.67, 105.25, 100.02, 
99.60, 64.75, 61.36, 61.10, 57.12, 56.78, 56.35, 46.25, 
43.63, 43.54, 43.03, 39.06, 32.96, 30.73, 26.27, 23.72. 
HRMS (ESI): [M+H]
+
Calcd for C47H52N2O6 
740.3825, found: 740.3817. 
 
5-(4-isopropoxyphenyl) tetrandrine (IVa) 
Light yellow solid; yield 54%; 7.34 (dd, J = 7.76 
Hz, 1H), 7.12 (dd, J = 7.27 Hz, 1H), 6.95 (s, 1H), 6.87 
(d, J = 3.7Hz, 1H), 6.82 (dd, J = 7.6 Hz, 1H), 6.56 (d, 
J = 2.1 Hz, 1H), 6.54 (d, J = 1.9 Hz, 1H), 6.53–6.49 
(m, 3H), 6.31 (dd, J = 8.3, 2.1 Hz, 1H), 6.10 (s, 1H), 
4.96 (s, 1H), 3.82 (s, 3H), 3.68 (s, 1H), 3.51 (s, 1H), 
3.49 (s, 3H), 3.47 (s, 1H), 3.43 (s, 3H), 3.39 (s, 1H), 
3.33 (s, 1H), 3.25 (s, 3H), 3.08–2.96 (m, 3H), 2.91–
2.77 (m, 5H), 2.71 (s, 1H), 2.68 (s, 3H), 2.29 (s, 3H) 
1.34(m,6H). 
13
C NMR (126 MHz, CDCl3) δ = 161.19, 
158.94, 154.87, 150.38, 149.47, 148.65, 148.27, 
144.95, 142.67, 135.98, 133.66, 133.01, 132.46, 
131.49, 129.28, 129.03, 128.60, 126.89, 123.89, 
122.86, 121.48, 121.11, 119.19, 117.14, 112.31, 
113.96, 112.69, 105.21, 100.12, 99.63, 73.45, 64.77, 
61.39, 61.16, 57.17, 56.81, 56.39, 46.29, 43.66, 43.52, 
43.12, 38.79, 32.87, 30.76, 26.28, 23.76, 22.93. 
HRMS (ESI): [M+H]
+
Calcd for C49H56N2O6 
768.4138, found: 768.4132. 
 
5-(4-isobutylphenyl) tetrandrine (IVc) 
Light yellow solid; yield 55%; Light yellow solid; 
yield 56%; 
1
H NMR (500 MHz, CDCl3) δ (ppm): 7.35 
(dd, J = 7.91 Hz, 1H), 7.15 (dd, J = 7.6 Hz, 1H), 6.94 
(s, 1H), 6.85 (d, J = 3.5 Hz, 1H), 6.81 (dd, J = 7.9 Hz, 
1H), 6.67 (d, J = 2.4 Hz, 1H), 6.61 (d, J = 2.7 Hz, 1H), 
6.57–6.51 (m, 3H), 6.37 (dd, J = 8.4 Hz, 1H), 6.07 (s, 
1H), 3.80 (s, 3H), 3.75 (s, 1H), 3.50 (s, 1H), 3.45 (s, 
3H), 3.43 (s, 1H), 3.40 (s, 3H), 3.36 (s, 1H), 3.33 (s, 
1H), 3.27 (s, 3H), 3.09–2.98 (m, 3H), 2.82–2.73 (m, 
5H), 2.73 (m, 1H), 2.69 (s, 1H), 2.65 (s, 3H),2.30 (s, 
3H), 1.97 (m, 1H), 1.12 (m, 6H). 
13
C NMR (126 MHz, 
CDCl3) δ = 161.20, 159.21, 154.64, 150.47, 149.48, 
148.54, 148.17, 145.13, 142.71, 136.12, 133.66, 
132.61, 132.47, 131.42, 129.92, 128.23, 128.87, 
126.80, 123.86, 122.80, 121.57, 121.15, 119.31, 
117.24, 112.37, 113.73, 112.69, 105.55, 100.62, 99.23, 
61.39, 61.17, 57.06, 56.38, 56.05, 49.65, 46.27, 43.63, 
43.56, 43.23, 39.17, 33.04, 32.10, 30.93, 25.62, 26.27, 
23.72. HRMS (ESI): [M+H]
+
Calcd for C50H58N2O5 
766.4346, found: 766.4361. 
 
5-(4-phenoxyphenyl) tetrandrine (IVa) 
Light yellow solid; yield 54%; 
1
H NMR (500 MHz, 
CDCl3) δ (ppm): 7.36 (dd, J = 6.7 Hz, 1H), 7.14 (dd, J 
= 8.3 Hz, 1H), 6.83 (s, 1H), 6.77 (d, J = 3.5 Hz, 1H), 
6.71 (dd, J = 7.9 Hz, 1H), 6.63 (d, J = 1.4 Hz, 1H), 
6.60-6.57 (m, 6H), 6.55–6.50 (m, 3H), 6.34 (dd, J = 
5.2Hz, 1H), 6.14 (s, 1H), 3.90(s, 3H), 3.79 (s, 3H), 3.71 
(s, 1H), 3.63 (s, 1H), 3.54 (s, 3H), 3.49 (s, 1H), 3.43 (s, 
3H), 3.39 (s, 1H), 3.36 (s, 1H), 3.32 (s, 3H), 3.16–3.03 
(m, 3H), 2.93–2.78 (m, 5H), 2.73 (s, 1H), 2.69 (s, 3H), 
2.27 (s, 3H). 
13
C NMR (126 MHz, CDCl3) δ = 160.82, 
160.03, 155.25, 151.56, 149.90, 148.84, 148.09, 
145.26, 142.35, 136.27, 133.57, 132.63, 132.22, 
131.97, 129.62, 128.33, 128.67, 126.53, 123.67, 
122.47, 121.63, 121.17, 119.29, 117.25, 112.43, 
113.63, 112.36, 105.25, 100.06, 99.32, 64.61, 61.70, 
61.22, 57.31, 56.87, 56.15, 46.49, 43.33, 43.24, 42.83, 
39.25, 32.66, 31.23, 27.17, 22.12. HRMS (ESI): 
[M+H]
+
Calcd for C52H54N2O6802.3982, found: 
802.3998. 
 
Biological Activity  
The inhibitory activities of IVa-IVdon HL60 cells 
and A549 cells are shown in (Fig. 1). It can be seen 
from figure 1 that compound IVa, IVb, and IVc have 
some significant (P <0.040) inhibitory activities. The 
inhibitory activity of IVa-IVd on protein tyrosine 
kinase is shown in Fig. 2. It can be seen from Fig. 2 
that the inhibitory activity of IVb and IVc on receptor 
tyrosine kinase FGFR1 is more than 47%, and the 
activity is higher than tetrandrine to some extent. In 
conclusion, IVa and IVb not only have some inhibitory 
activity on HL60 and A549 cells but also have high 
selectivity for tyrosine kinase FGFR1. It can be further 




Fig. 1 — Inhibition activities of IVa-IVd against HL60 and A549 
human cancer cell lines 
 






Four new derivatives of tetrandrine were 
synthesized and analyzed for their structural details. 
The preliminary antitumor activity showed that IVa, 
IVb, and IVc had some significant (P <0.040) 
inhibitory activity on HL60 cells and A549 cells. 
Among them, IVa and IVb have highly significant  
(P <0.001) inhibitory activity on receptor tyrosine 
kinase FGFR1, which can be further modified as 
potential drugs. On the basis of this study, the 
antitumor activity, structure-activity relationship, and 
mechanism of action of other compounds of the same 
series are in progress in order to obtain more effective 
antitumor drugs. 
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Fig. 2 — Inhibition ratio of VIa-IVd against different PTKs 
 
